Key result
A 17-year-old male with COVID-19 vaccine-associated myocarditis developed a 3-beat run of nonsustained ventricular tachycardia at 230 bpm during an exercise stress test 6 months after diagnosis.
Why the study?
The long-term outcomes of COVID-19 vaccine-associated myocarditis are unclear.
Case Report (n=1)
Highlights the potential for late ventricular arrhythmias in patients with a history of COVID-19 vaccine-associated myocarditis, suggesting a need for careful follow-up.
Answers are grounded in this paper and cite their sources.
NSVT at 6 months after vaccine myocarditis warrants extended arrhythmia surveillance in adolescents; leaves open long-term risk and monitoring needs.
17-year-old male presented with COVID-19 vaccine-associated myocarditis. Six months later, due to chest discomfort with exercise, the patient underwent an exercise stress test that revealed a 3-beat run of nonsustained ventricular tachycardia at 230 bpm at peak exercise. The long-term outcomes of COVID-19 vaccine-associated myocarditis are unclear. This patient had nonsustained ventricular tachycardia over 6 months after diagnosis.
No takes yet. Share an insight, caveat, or question.
Sheth et al. (2023) conducted a case report in COVID-19 vaccine-associated myocarditis (n=1). COVID-19 vaccine was evaluated on Nonsustained ventricular tachycardia. A 17-year-old male with COVID-19 vaccine-associated myocarditis developed a 3-beat run of nonsustained ventricular tachycardia at 230 bpm during an exercise stress test 6 months after diagnosis.
Synapse has enriched 10 related papers. Consider them for comparative context: